Momenta Pharmaceuticals Announces Date Of Earnings Release And Conference Call For Fourth Quarter And Year End 2010 Financial Results

CAMBRIDGE, Mass., Jan. 27, 2011 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will report its financial results for the fourth quarter and year ended December 31, 2010 before the U.S. financial markets open on Thursday, February 10, 2011.

Management will host a conference call on that date at 10:00 am EST to discuss these results and provide an update on the company. To access the call, please dial [phone] (domestic) or [phone](international) prior to the scheduled conference call time and provide the access code 38546405. A replay of the call will be available approximately two hours after the conclusion of the call and will be accessible through February 24, 2011. To access the replay, please dial [phone] (domestic) or [phone] (international) and provide the access code 38546405.

A live audio webcast of the call will be available on the "Investors" section of the Company's website, www.momentapharma.com . Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call.

About Momenta

Momenta Pharmaceuticals is a biotechnology company, headquartered in Cambridge, MA, specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs.  

To receive additional information about Momenta, please visit the website at www.momentapharma.com , which does not form a part of this press release.   Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

CONTACT: Beverly Holley
         Momenta Pharmaceuticals, Inc.
         617-395-5189

>To order reprints of this article, click here: Reprints